Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

China Lymphoma Patient Registry Study (CLAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03313271
Recruitment Status : Recruiting
First Posted : October 18, 2017
Last Update Posted : October 18, 2017
Sponsor:
Collaborators:
Peking University First Hospital
Tianjin Medical University Cancer Hospital
Zhejiang Cancer Hospital
Heilongjiang Cancer Hospital
Sipai(Beijing)Network Technology Co Ltd
Information provided by (Responsible Party):
Jun Zhu, Peking University

Brief Summary:

Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With the progress of treatment, the survival rate of lymphoma patients has been improved. But the 5 year survival rate of lymphoma in China is shorter than that in United States. The reason is that there is still a gap between China and the United States in disease screening, diagnosis and treatment.

Observational studies, especially cohort studies, are important tools for understanding disease progression, treatment, and prognosis in the real world. Observational cohort studies which involve over 500 patients are currently launched by South Korea and the United States. China, which has more patients, doesn't have a cohort of patients with lymphoma. So the primary objective of this study was to establish an observational cohort of patients with lymphoma in China and follow up the patients for a long period of time to provide basic support for clinical research and drug development, and continuously improve patient outcomes and quality of life. The secondary objective is to collect information about diagnosis, treatment, follow-up and prognosis of lymphoma.


Condition or disease
Lymphoma

Detailed Description:

Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With the progress of treatment, the survival rate of lymphoma patients has been improved. But the 5 year survival rate of lymphoma in China is shorter than that in United States. The reason is that there is still a gap between China and the United States in disease screening, diagnosis and treatment.

Observational studies, especially cohort studies, are important tools for understanding disease progression, treatment, and prognosis in the real world. Observational cohort studies which involve over 500 patients are currently launched by South Korea and the United States. China, which has more patients, doesn't have a cohort of patients with lymphoma. So the primary objective of this study was to establish an observational cohort of patients with lymphoma in China and follow up the patients for a long period of time to provide basic support for clinical research and drug development, and continuously improve patient outcomes and quality of life. The secondary objective is to collect information about diagnosis, treatment, follow-up and prognosis of lymphoma.


Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 5000 participants
Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration: 5 Years
Official Title: China Lymphoma Patient Registry Study
Actual Study Start Date : May 17, 2017
Estimated Primary Completion Date : May 17, 2027
Estimated Study Completion Date : August 30, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Group/Cohort
a cohort of patients with lymphoma in China
establish a cohort of patients with lymphoma in China and follow up the patients for a long period of time



Primary Outcome Measures :
  1. Characteristics of lymphoma in China, [ Time Frame: 5 years ]
    Understand the characteristics of lymphoma in China,such as the distribution of sex,age,histological type and clinical stage etc


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 10 years ]
    Overall survival is defined as the time from disease to death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Lymphoma patients in 5 hospitals
Criteria

Inclusion Criteria:

  • The disease was diagnosed by Hodgkin's or non Hodgkin's lymphoma
  • 18 years of age or older at diagnosis
  • The diagnosis was confirmed within 6 months before admission
  • Informed consent was obtained

Exclusion Criteria:

  • There are no special exclusion criteria in this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03313271


Contacts
Layout table for location contacts
Contact: Yuqin Song, Ph D 0086 ‭13683398726‬ songyuqin622@163.com

Locations
Layout table for location information
China, Beijing
Peking University Cancer Hospital Recruiting
Beijing, Beijing, China, 100142
Contact: Yuqin Song, Ph D    13683398726    songyuqin622@163.com   
Sponsors and Collaborators
Jun Zhu
Peking University First Hospital
Tianjin Medical University Cancer Hospital
Zhejiang Cancer Hospital
Heilongjiang Cancer Hospital
Sipai(Beijing)Network Technology Co Ltd
Investigators
Layout table for investigator information
Principal Investigator: Jun Zhu, Ph D Beijing Cancer Hospital

Additional Information:

Publications:
Layout table for additonal information
Responsible Party: Jun Zhu, Director of lymphoma department, Peking University
ClinicalTrials.gov Identifier: NCT03313271     History of Changes
Other Study ID Numbers: h-yx-bj-16003
First Posted: October 18, 2017    Key Record Dates
Last Update Posted: October 18, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jun Zhu, Peking University:
lymphoma
CLAP
China
patient registry
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases